Introduction:
WuXi Biologics will invest US$1.4 billion over ten years in a new CRDMO facility in Singapore.
Features:
The company will increase its capacity and capabilities for large-scale drug substance and drug product (DS/DP) manufacture as part of the plan.
Additionally, it will construct a new bio-manufacturing plant that will add 120,000 litres of capacity by 2026 and hire 1,500 specialized workers for manufacture, research, and development.
The facility will also assist WuXi Biologics' Global Dual Sourcing Strategy which aims to minimize risks by ensuring that customer projects can be completed at several locations around the world.
Specifications:
| Name | WuXi Biologics |
| Type | Expansion |
| Budget | US$1.4 billion |
| Year | 2026 |
